Explore our materials

Filters

Results (5220)

Slideset

HIV

Spanish HIV Clinical Forum 2017

Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano

Slideset

HIV

Spanish HIV Clinical Forum 2017

Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos

Charles Boucher

MD, PhD

Slideset

HIV

Spanish HIV Clinical Forum 2017

HIV Prevention 2.0- Charles Boucher, MD, PhD

Slideset

HIV

Spanish HIV Clinical Forum 2017

Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD

Slideset

HIV

Spanish HIV Clinical Forum 2017

Virological perspective- Santiago Moreno, MD

Slideset

HIV

Spanish HIV Clinical Forum 2017

Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD

José Moltó

MD, PhD

Slideset

HIV

Spanish HIV Clinical Forum 2017

Pharmacological perspective- José Moltó, MD, PhD

Jonathan Schapiro

Slideset

HIV

Spanish HIV Clinical Forum 2017

Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MD

Slideset

HIV

Spanish HIV Clinical Forum 2017

Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. Viciana

Slideset

HIV

Spanish HIV Clinical Forum 2017

Mutaciones a Inhibidores de la Integrasa en la vida real- I. Viciana

Slideset

HIV

Spanish HIV Clinical Forum 2017

Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016 - M. Casadellà

Jose Arribas

Slideset

HIV

Spanish HIV Clinical Forum 2017

Explore our materials

Your Selection Clear All

Topic

Material Type

Dolutegravir and lamivudine as dual maintenance therapy- R. Montejano

Eficacia y seguridad de dolutegravir más rilpivirina en la vida real. Resultados a 24 semanas. Estudio DORIVIR- J. Santos

HIV Prevention 2.0- Charles Boucher, MD, PhD

Clinical case on reduced drug regimen with integrase inhibitors- Federico Pulido, MD

Virological perspective- Santiago Moreno, MD

Toxicity and co-morbidities perspective- José Ignacio Bernardino, MD

Pharmacological perspective- José Moltó, MD, PhD

Reduced drug regimens, what’s the magic number: three, two or one? – Overview- Jonathan Schapiro, MD

Transmisión de mutaciones de resistencias a inhibidores de la integrasa- I. Viciana

Mutaciones a Inhibidores de la Integrasa en la vida real- I. Viciana

Primary Resistance to Integrase Strand-Transfer Inhibitors in Spain, 2015-2016 - M. Casadellà

2016-2017 - Key Advances in HIV Treatment- José Arribas, MD